BioSpace News Archive

Detailed results from the positive Phase III THALES trial showed AstraZeneca’s BRILINTA® 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate of the primary composite endpoint of stroke and death by 17%, compared to aspirin alone in patients who had an acute ischemic stroke or transient ischemic attack.

Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, announced that Jodie P. Morrison has assumed the chair role of its board of directors, effective July 15, 2020.

Humanigen’s investigational monoclonal antibody, lenzilumab, was developed using Catalent’s proprietary GPEx® cell line development technology

Bristol-Myers Squibb Company announced the expiration and final results of its offers to exchange any and all of its outstanding $19,000,000,000 aggregate principal amount of senior unsecured notes previously issued on May 16, 2019 pursuant to an exemption from the registration requirements of the Securities Act of 1933

AngioDynamics, Inc., a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced financial results for the fourth quarter of fiscal year 2020, which ended May 31, 2020.

Biodesix, Inc., a leader in lung cancer diagnostics, announced the publication of research findings on a diagnostic test capable of generating valuable data to help guide the treatment of patients with advanced non-small cell lung cancer.

The United States Food and Drug Administration has approved one-way digital data streaming during patient support from Abiomed’s Automated Impella Controller, the external console used with Impella heart pumps.

Multi-center dose escalation and expansion study will assess safety, tolerability and preliminary efficacy of treatment with ONCR-177 alone and in combination with Merck’s KEYTRUDA® (pembrolizumab)

Oncorus Announces Clinical Trial Collaboration with Merck to Evaluate the Combination of Oncorus’ ONCR-177 with Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors

F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific antibodies, announces further progress in its long-standing immuno-oncology collaboration with Merck KGaA, Darmstadt, Germany.